LCTX Stock Summary and Trading Ideas (Lineage Cell Therapeutics | AMEX:LCTX)

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Lineage Cell Therapeutics trades on the AMEX stock market under the symbol LCTX.

As of January 30, 2025, LCTX stock price climbed to $0.63 with 582,570 million shares trading.

LCTX has a beta of 0.80, meaning it tends to be less sensitive to market movements. LCTX has a correlation of 0.02 to the broad based SPY ETF.

LCTX has a market cap of $143.84 million. This is considered a Micro Cap stock.

Last quarter Lineage Cell Therapeutics reported $4 million in Revenue and -$.02 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.01.

In the last 3 years, LCTX traded as high as $1.79 and as low as $.48.

The top ETF exchange traded funds that LCTX belongs to (by Net Assets): IWM, VTI, VXF, IWO, VTWO.

LCTX has underperformed the market in the last year with a return of -37.4%, while the SPY ETF gained +24.7%. In the last 3 month period, LCTX fell short of the market, returning -26.5%, while SPY returned +4.7%. However, in the most recent 2 weeks LCTX has outperformed the stock market by returning +9.6%, while SPY returned +2.3%.

LCTX support price is $.57 and resistance is $.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LCTX shares will trade within this expected range on the day.